PYXS revenueQ4 2025$11.04M
- FY YoY
- -14.2%
PYXS revenue was $11.04M in fiscal Q4 2025 (ended Dec 31, 2025), compared with $0 a year earlier. For the full fiscal 2025 it was $13.86M, down 14.2% from fiscal 2024.
Pyxis Oncology Inc. (PYXS) financials
For fiscal 2025 (ended Dec 31, 2025), Pyxis Oncology Inc. reported $13.86M of revenue and -$79.62M of net income.
- Revenue, FY2025
- $13.86M
- Revenue growth, YoY
- -14.2%
- Net income, FY2025
- -$79.62M
- Net margin
- -574.5%
- Free cash flow, FY2025
- -$63.51M
- EPS, diluted, FY2025
- -$1.28
- Cash
- $3.86M
- P/S
- 14.67
- Market cap
- $203.3M
FY2024FY2025
FY2020FY2025
FY2020FY2025
PYXS revenue and earnings growth
PYXS net incomeQ3 2026-$19.98M
PYXS net income was -$19.98M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$22.00M a year earlier. For the full fiscal 2025 it was -$79.62M, compared with -$77.33M in fiscal 2024.
PYXS EPSQ3 2026-$0.24
PYXS diluted EPS was -$0.24 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.35 a year earlier. For the full fiscal 2025 it was -$1.28, compared with -$1.32 in fiscal 2024.
PYXS free cash flowQ4 2025-$10.43M
PYXS free cash flow was -$10.43M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$19.29M a year earlier. For the full fiscal 2025 it was -$63.51M, compared with -$57.91M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | $13.86M | $16.15M | - | - | - | - |
| Cost of revenue | $2.39M | $475.0K | - | - | - | - |
| Gross profit | $11.47M | $15.67M | - | - | - | - |
| Research and development | $73.70M | $58.75M | $49.59M | $86.13M | $51.05M | $9.05M |
| Selling, general and admin | $22.19M | $25.42M | $32.61M | $37.35M | $18.66M | $3.85M |
| Operating income | -$84.42M | -$89.46M | -$82.20M | -$123.48M | -$69.72M | -$12.89M |
| Pre-tax income | -$78.23M | -$79.50M | -$73.79M | - | - | - |
| Income tax | $1.39M | -$2.16M | - | - | - | - |
| Net income | -$79.62M | -$77.33M | -$73.79M | -$120.72M | -$75.97M | -$12.83M |
| EPS, basic | -$1.28 | -$1.32 | -$1.85 | -$3.65 | -$8.95 | -$12.45 |
| EPS, diluted | -$1.28 | -$1.32 | -$1.85 | -$3.65 | -$8.95 | -$12.45 |
| Diluted shares | 62.1M | 58.4M | 39.9M | 33.0M | 8.5M | 1.0M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $15.42M | $19.47M | $9.66M | $179.29M | $274.74M | $8.08M |
| Short-term investments | $51.44M | $107.46M | $109.63M | - | - | - |
| Current assets | $72.11M | $132.44M | $124.60M | $186.61M | $278.67M | $8.10M |
| Total assets | $91.52M | $157.18M | $173.73M | $211.38M | $280.02M | $10.15M |
| Current liabilities | $21.13M | $17.68M | $25.76M | $31.63M | $18.71M | $3.69M |
| Total liabilities | $38.11M | $36.43M | $48.02M | $50.55M | $18.71M | $3.85M |
| Shareholders' equity | $53.41M | $120.75M | $125.70M | $160.82M | $261.31M | -$15.64M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$63.50M | -$57.67M | -$70.71M | -$89.33M | -$35.33M | -$10.08M |
| Capital expenditures | $9.0K | $237.0K | $6.73M | $6.40M | $540.0K | $1.48M |
| Free cash flow | -$63.51M | -$57.91M | -$77.44M | -$95.73M | -$35.87M | -$11.57M |
| Investing cash flow | $58.86M | $8.15M | -$104.85M | -$6.40M | -$590.0K | -$1.48M |
| Financing cash flow | $594.0K | $59.33M | $5.93M | $183.0K | $304.04M | $35.0K |
| Stock-based compensation | $11.80M | $12.95M | $16.95M | $15.76M | $6.44M | $44.0K |
| Depreciation and amortization | $4.51M | $2.98M | $1.93M | $709.0K | $647.0K | $469.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | -14.2% | - | - | - | - | - |
| Gross margin | 82.8% | 97.1% | - | - | - | - |
| Operating margin | -609.2% | -554.1% | - | - | - | - |
| Net margin | -574.5% | -478.9% | - | - | - | - |
| Free cash flow margin | -458.3% | -358.7% | - | - | - | - |
| Return on equity | -149.1% | -64.0% | -58.7% | -75.1% | -29.1% | - |
| Return on assets | -87.0% | -49.2% | -42.5% | -57.1% | -27.1% | -126.4% |
| Current ratio | 3.41 | 7.49 | 4.84 | 5.90 | 14.90 | 2.20 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $11.04M | $0 | $2.82M | $0 | $0 | $0 | $0 | $16.15M | - |
| Cost of revenue | - | - | - | - | - | - | - | $0 | $0 | $0 | $475.0K | - |
| Gross profit | - | - | - | - | - | - | - | $0 | $0 | $0 | $15.67M | - |
| Research and development | $16.56M | $16.06M | $19.98M | $21.71M | $17.81M | $17.13M | $17.04M | $14.02M | $17.74M | $13.95M | $13.03M | $11.61M |
| Selling, general and admin | $3.97M | $9.93M | $4.38M | $5.23M | $5.65M | $5.44M | $5.87M | $5.08M | $6.01M | $6.08M | $8.25M | $6.16M |
| Operating income | -$20.52M | -$25.99M | -$24.36M | -$18.30M | -$23.46M | -$19.75M | -$22.91M | -$40.07M | -$23.75M | -$20.03M | -$5.61M | -$17.77M |
| Pre-tax income | -$19.98M | -$25.35M | -$23.27M | -$17.00M | -$22.00M | -$18.07M | -$21.16M | -$37.73M | -$21.20M | -$17.30M | -$3.26M | - |
| Income tax | $0 | $0 | $0 | $1.10M | $0 | $283.0K | $0 | - | - | - | - | - |
| Net income | -$19.98M | -$25.35M | -$23.27M | -$18.11M | -$22.00M | -$18.35M | -$21.16M | -$35.57M | -$21.20M | -$17.30M | -$3.26M | -$15.60M |
| EPS, basic | -$0.24 | -$0.40 | -$0.37 | -$0.28 | -$0.35 | -$0.30 | -$0.35 | -$0.62 | -$0.35 | -$0.29 | -$0.06 | -$0.34 |
| EPS, diluted | -$0.24 | -$0.40 | -$0.37 | -$0.28 | -$0.35 | -$0.30 | -$0.35 | -$0.62 | -$0.35 | -$0.29 | -$0.06 | -$0.34 |
| Diluted shares | 83.5M | 64.0M | 63.5M | - | 62.6M | 61.9M | 61.0M | - | 60.7M | 60.5M | 51.3M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.86M | $18.86M | $5.77M | $15.42M | $8.92M | $10.73M | $12.76M | $19.47M | $12.06M | $25.07M | $27.97M | $9.66M |
| Short-term investments | $51.72M | $14.14M | $35.25M | $51.44M | $67.34M | $78.21M | $92.67M | $107.46M | $132.76M | $130.65M | $129.06M | $109.63M |
| Receivables | - | - | - | - | - | $3.00M | - | - | - | - | $8.00M | - |
| Current assets | $59.13M | $36.73M | $45.57M | $72.11M | $83.07M | $99.96M | $111.87M | $132.44M | $148.87M | $161.04M | $172.38M | $124.60M |
| Total assets | $76.77M | $54.92M | $64.30M | $91.52M | $105.60M | $123.22M | $135.87M | $157.18M | $195.31M | $208.39M | $220.22M | $173.73M |
| Current liabilities | $19.94M | $27.47M | $16.53M | $21.13M | $19.38M | $17.68M | $14.43M | $17.68M | $20.32M | $16.90M | $14.14M | $25.76M |
| Total liabilities | $35.45M | $43.48M | $33.03M | $38.11M | $36.83M | $35.57M | $32.76M | $36.43M | $41.63M | $38.59M | $36.06M | $48.02M |
| Shareholders' equity | $41.32M | $11.44M | $31.27M | $53.41M | $68.78M | $87.64M | $103.10M | $120.75M | $153.68M | $169.79M | $184.16M | $125.70M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.29M | -$18.21M | -$26.00M | -$10.43M | -$13.28M | -$17.26M | -$22.54M | -$19.29M | -$14.66M | -$3.01M | -$20.71M | -$15.25M |
| Capital expenditures | - | - | - | $0 | - | - | - | $0 | $0 | $0 | $237.0K | $0 |
| Free cash flow | - | - | - | -$10.43M | - | - | - | -$19.29M | -$14.66M | -$3.01M | -$20.95M | -$15.25M |
| Investing cash flow | -$37.29M | $21.30M | $16.37M | $16.26M | $11.47M | $15.30M | $15.82M | $26.66M | -$8.0K | $4.0K | -$18.50M | $10.23M |
| Financing cash flow | $38.59M | $9.99M | -$25.0K | $669.0K | -$8.0K | -$67.0K | $0 | $50.0K | $1.66M | $110.0K | $57.51M | -$25.0K |
| Stock-based compensation | $1.33M | $5.53M | $1.21M | $2.08M | $3.07M | $3.02M | $3.63M | $2.77M | $2.98M | $2.87M | $4.32M | $3.21M |
| Depreciation and amortization | $299.0K | $301.0K | $459.0K | $2.90M | $527.0K | $535.0K | $552.0K | $550.0K | $731.0K | $585.0K | $1.12M | $690.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | -100.0% | - | - | - | - | - |
| Gross margin | - | - | - | - | - | - | - | - | - | - | 97.1% | - |
| Operating margin | - | - | - | -165.7% | - | -700.4% | - | - | - | - | -34.7% | - |
| Net margin | - | - | - | -164.0% | - | -650.9% | - | - | - | - | -20.2% | - |
| Free cash flow margin | - | - | - | -94.5% | - | - | - | - | - | - | -129.7% | - |
| Current ratio | 2.96 | 1.34 | 2.76 | 3.41 | 4.29 | 5.65 | 7.75 | 7.49 | 7.33 | 9.53 | 12.19 | 4.84 |
Source: XBRL data Pyxis Oncology Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
PYXS peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PYXS | $13.86M | -14.2% | -$79.62M | -574.5% | $203.3M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
PYXS FAQ
9 questionsWhat is PYXS revenue?
Pyxis Oncology Inc. (PYXS) reported $13.86M of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 14.2% from the year before.Is PYXS profitable?
No. Pyxis Oncology Inc. reported a net loss of $79.62M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does PYXS have?
Pyxis Oncology Inc. reported $3.86M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is PYXS revenue growing?
Pyxis Oncology Inc.'s revenue changed -14.2% in fiscal 2025, to $13.86M.What is PYXS gross margin?
Pyxis Oncology Inc.'s gross profit was $11.47M on $13.86M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 82.8%.What is PYXS free cash flow?
Pyxis Oncology Inc. generated -$63.51M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$63.50M less capital expenditures.What is PYXS earnings per share?
Diluted earnings per share were -$1.28 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did PYXS last report financial results?
The latest statements here come from Pyxis Oncology Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this PYXS financial data come from?
Quantisnow builds these statements from the structured XBRL data Pyxis Oncology Inc. files with the SEC. It is provided for information only and is not investment advice.